Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Daewoong Co., Ltd. (003090:KRX), powered by AI.
Daewoong Co., Ltd. is currently trading at ₩16,330. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Daewoong Co., Ltd. on Alpha Lenz.
Daewoong Co., Ltd.'s P/E ratio is 3.8.
“Daewoong Co., Ltd. trades at a P/E of 3.8 (undervalued) with strong ROE of 16.1%.”
Ask for details →Daewoong Co., Ltd. is a prominent pharmaceutical company primarily engaged in the development, manufacture, and distribution of medicines, medical devices, and healthcare-related products. Founded in South Korea, Daewoong has established itself as a key player in the global pharmaceutical industry. The company's primary focus is on providing innovative and effective healthcare solutions, which encompass a wide range of therapeutic areas including gastrointestinal, anti-diabetic, and cardiovascular treatments. Daewoong is particularly known for its robust research and development initiatives, which aim to address unmet medical needs through cutting-edge technologies and strategic collaborations. The firm plays a significant role in the pharmaceutical supply chain, contributing to the availability of essential medicines and healthcare solutions across both domestic and international markets. Through its commitment to quality and continuous innovation, Daewoong Co., Ltd. remains a vital entity in the advancement of global health and well-being.
“Daewoong Co., Ltd. trades at a P/E of 3.8 (undervalued) with strong ROE of 16.1%.”
Ask for details →Daewoong Co., Ltd. (ticker: 003090) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 356 employees. Market cap is $949.5B.
The current price is ₩16,330 with a P/E ratio of 3.82x and P/B of 0.57x.
ROE is 16.11% and operating margin is 12.66%. Annual revenue is $2.1T.